Cetuximab

證據等級: L5

預測適應症: 10 個

Cetuximab: From Anti-EGFR Oncology Therapy to Bronchial Adenomas/Carcinoids, Childhood

One-Sentence Summary

Cetuximab is an anti-EGFR chimeric monoclonal antibody; this evidence pack does not contain a Taiwan-approved indication text or formal MOA record (both flagged as data gaps), but the embedded trial/literature background consistently identifies it as an established therapy for EGFR-overexpressing head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (mCRC). The TxGNN model's top-ranked prediction is Bronchial Adenomas/Carcinoids, Childhood, but this candidate is currently supported by 0 clinical trials and 0 publications — it is a pure model prediction (L5). Two other candidates further down the ranked list (Cystic Neoplasm and Pre-malignant Neoplasm) have meaningfully stronger evidence (L2, Research Question stage) and are summarized separately below.

Quick Overview

Item	Content
Original Indication	Not specified in Taiwan regulatory data (no local market license on file). Internationally, cetuximab is an established anti-EGFR therapy for HNSCC and RAS/BRAF wild-type mCRC, as referenced throughout the embedded trial/literature background of this pack.
Predicted New Indication	Bronchial Adenomas/Carcinoids, Childhood
TxGNN Prediction Score	99.95%
Evidence Level	L5 (model prediction only, no supporting studies)
Taiwan Market Status	Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data for cetuximab is not available in this evidence pack (data gap DG002). Based on the background context embedded across the trial and literature evidence in this pack, cetuximab is known to be a chimeric IgG1 monoclonal antibody that blocks the epidermal growth factor receptor (EGFR), and its efficacy has been established in EGFR-overexpressing tumors — chiefly HNSCC and mCRC — through decades of trials referenced throughout this dataset (e.g., NCT00265941, NCT01302834, NCT00056030).

For the top-ranked candidate specifically, the model's own rationale is explicit that the mechanistic link is weak: bronchial adenomas/carcinoids of childhood are neuroendocrine tumors, not a typical EGFR-driven malignancy, and the pediatric population lacks any cetuximab safety data. In other words, this is the case where a high TxGNN similarity score does not correspond to a plausible biological mechanism — the prediction should be treated as hypothesis-generating only, not as a candidate for further development at this time.

By contrast, further down the ranked list, two candidates show a much more coherent mechanistic story consistent with cetuximab's known EGFR-blockade action: adenoid cystic carcinoma (within the "cystic neoplasm" category) and chemoprevention of EGFR-overexpressing pre-malignant upper aerodigestive lesions (within "pre-malignant neoplasm"). These are discussed in the overview section below.

Clinical Trial Evidence (Top-Ranked Candidate: Bronchial Adenomas/Carcinoids, Childhood)

Currently no related clinical trials registered.

Literature Evidence (Top-Ranked Candidate: Bronchial Adenomas/Carcinoids, Childhood)

Currently no related literature available.

Taiwan Market Information

No Taiwan market authorizations are on file for cetuximab in this evidence pack (total_licenses = 0, market_status = 未上市).

Other Predicted Indications in This Evidence Pack

This evidence pack contains 10 TxGNN-predicted indications for cetuximab, ranging from L5 (no supporting evidence) to L2 (Phase II trial + review-level literature support). For completeness and to avoid burying stronger signals, all 10 are summarized below.

Rank	Disease	TxGNN Score	Evidence Level	Decision Stage	Recommendation	Trials	Literature
1	Bronchial adenomas/carcinoids, childhood	99.95%	L5	S0	Hold	0	0
2	Non-seminomatous lesion	99.95%	L5	S0	Hold	0	0
3	Ductal or ductular proliferation	99.95%	L4	S0	Hold	0	20
4	Chondroid hamartoma	99.95%	L5	S0	Hold	0	0
5	Tumor of testis and paratestis	99.95%	L5	S0	Hold	0	0
6	Odontogenic cyst	99.95%	L4	S0	Hold	0	2
7	Thyroglossal duct cyst	99.95%	L5	S0	Hold	0	0
8	Cystic neoplasm	99.95%	L2	S2	Research Question	5	20
9	Epiglottis neoplasm	99.95%	L5	S1	Research Question	0	0
10	Pre-malignant neoplasm	99.95%	L2	S2	Research Question	~50	2

Notable candidate — Cystic Neoplasm (Rank 8)

The strongest single piece of evidence in this pack is a directly matched Phase I/II trial for adenoid cystic carcinoma (a "cystic neoplasm" subtype):

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01192087	Phase 1/2	Unknown	49	ACCEPT trial: cetuximab + IMRT + carbon-ion boost for adenoid cystic carcinoma; graded "A" relevance in the source evidence pack

Supporting literature (RCT/prospective evidence prioritized):

PMID	Year	Type	Journal	Key Findings
18804410	2009	Phase II prospective trial	Oral Oncology	Cetuximab monotherapy in recurrent/metastatic salivary gland carcinomas (23 adenoid cystic carcinoma patients); clinical benefit rate reported
18366287	2008	Review	Expert Rev Anticancer Ther	Systemic therapy options, including anti-EGFR agents, for recurrent/metastatic salivary gland cancers
22144378	2013	Case report	Head & Neck	Metastatic adenoid cystic carcinoma responding to cetuximab + weekly paclitaxel after paclitaxel-alone failure

Notable candidate — Pre-malignant Neoplasm (Rank 10)

A dedicated single-agent Phase II trial exists in high-risk pre-malignant upper aerodigestive lesions, plus a review directly addressing EGFR-targeted chemoprevention:

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00524017	Phase 2	Completed	35	Single-agent cetuximab in high-risk pre-malignant upper aerodigestive lesions

PMID	Year	Type	Journal	Key Findings
24412287	2014	Review	Oral Oncology	EGFR is overexpressed in oral pre-malignant lesions; discusses EGFR-targeted chemoprevention rationale for HNSCC

Important caveat: as the source rationale notes, the majority of the ~50 trials tagged to this candidate (e.g., NCT00956007, NCT05959356, NCT00056030) actually enrolled patients with already-diagnosed HNSCC/CRC rather than true pre-malignant lesions. Only NCT00524017 is a genuine chemoprevention trial. This distinction matters because treatment-population risk/benefit does not transfer directly to a chemoprevention setting.

Cytotoxicity

Cetuximab is an antineoplastic agent (anti-EGFR monoclonal antibody used in HNSCC/mCRC per the embedded trial background), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (anti-EGFR chimeric IgG1 monoclonal antibody) — not a conventional cytotoxic agent
Myelosuppression Risk	Not quantified in this evidence pack; please refer to the package insert warnings and precautions
Emetogenicity Classification	Not quantified in this evidence pack; please refer to the package insert warnings and precautions
Monitoring Items	Infusion-related reactions/hypersensitivity (referenced in NCT00896896 "Immunoreactivity to Cetuximab in Cancer Patients," n=538, and PMID 39415301 severe infusion reaction case report); skin toxicity (referenced in PMID 30141310, skin disorders as a prognostic factor in mCRC)
Handling Protection	Not specified in this evidence pack (TFDA label data is a blocking data gap, DG001); please refer to the package insert

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data are all marked as data gaps in this evidence pack (DG001, blocking severity), and no DDI records were found (query_status: not_found).

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked TxGNN prediction (bronchial adenomas/carcinoids, childhood) has zero supporting clinical trials or literature and is explicitly flagged by the model's own rationale as mechanistically implausible (non-EGFR-driven neuroendocrine tumor, no pediatric safety data). This candidate does not meet the bar for further evaluation at this time.

To proceed, the following is needed:

Resolve DG001 (blocking): obtain TFDA label warnings/contraindications before any S1 safety screening can occur
Resolve DG002 (high): obtain formal DrugBank MOA record to properly evaluate mechanistic plausibility across all 10 candidates
If pursuing repurposing work on this drug, redirect attention to the two evidence-backed candidates identified in this pack — Cystic Neoplasm (adenoid cystic carcinoma, L2/Research Question, Phase I/II trial + Phase II prospective literature) and Pre-malignant Neoplasm (EGFR chemoprevention, L2/Research Question, dedicated Phase II trial) — rather than the top-ranked but evidence-free candidate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.